Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome

被引:46
作者
Avcin, T.
Silverman, E. D.
机构
[1] Univ Ljubljana, Med Ctr, Univ Childrens Hosp, Dept Allergol, SL-1525 Ljubljana, Slovenia
[2] Univ Ljubljana, Med Ctr, Univ Childrens Hosp, Dept Rheumatol, Ljubljana 61000, Slovenia
[3] Univ Ljubljana, Med Ctr, Univ Childrens Hosp, Dept Clin Immunol, Ljubljana 61000, Slovenia
[4] Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada
[5] Univ Toronto, Hosp Sick Children, Dept Immunol, Div Rheumatol, Toronto, ON M5G 1X8, Canada
关键词
D O I
10.1177/0961203307079036
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The anti phospholipid syndrome (APS) is recognized increasingly as the most common acquired hypercoagulation state of autoimmune etiology and may occur as an isolated clinical entity (primary APS) or in association with an underlying systemic disease, particularly systemic lupus erythematosus (SLE). The major differences between pediatric and adult APS include absence of common acquired risk factors for thrombosis, absence of pregnancy-related morbidity, increased incidence of infection-induced antibodies, differences in CM-Off values for determination of aPL and specific factors regarding long-term therapy in children. APS in children has been largely reported in patients with arterial or venous thromboses and less frequently in association with neurological or hematological manifestations. The presence of aPL in pediatric SLE can modify the disease expression and may be an important predictor of the development of irreversible organ damage. Two recently established international registries of neonates and children with APS provide a good opportunity to conduct large, prospective studies on the clinical significance of aPL and long-term outcome of pediatric APS.
引用
收藏
页码:627 / 633
页数:7
相关论文
共 72 条
[1]   Anti-β2-glycoprotein I antibodies in children with atopic dermatitis [J].
Ambrozic, A ;
Avicin, T ;
Ichikawa, K ;
Kveder, T ;
Matsuura, E ;
Hojnik, M ;
Atsumi, T ;
Rozman, B ;
Koike, T .
INTERNATIONAL IMMUNOLOGY, 2002, 14 (07) :823-830
[2]   Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines [J].
Asherson, RA ;
Cervera, R ;
de Groot, PG ;
Erkan, D ;
Boffa, MC ;
Piette, JC ;
Khamashta, MA ;
Shoenfeld, Y .
LUPUS, 2003, 12 (07) :530-534
[3]   Recent advances in antiphospholipid antibodies and antiphospholipid syndromes in pediatric populations [J].
Avcin, T ;
Cimaz, R ;
Meroni, PL .
LUPUS, 2002, 11 (01) :4-10
[4]  
Avcin T, 2002, CLIN EXP RHEUMATOL, V20, P101
[5]   Anticardiolipin and anti-β2 glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits [J].
Avcin, T ;
Ambrozic, A ;
Kuhar, M ;
Kveder, T ;
Rozman, B .
RHEUMATOLOGY, 2001, 40 (05) :565-573
[6]  
AVCIN T, UNPUB LONGITUDINAL F
[7]   Antiphospholipid syndrome and recurrent thrombosis in children [J].
Berkun, Y. ;
Padeh, S. ;
Barash, J. ;
Uziel, Y. ;
Harel, L. ;
Mukamel, M. ;
Revel-Vilk, S. ;
Kenet, G. .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2006, 55 (06) :850-855
[8]   The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: A cross-sectional study [J].
Berube, C ;
Mitchell, L ;
Silverman, E ;
David, M ;
Saint Cyr, C ;
Laxer, R ;
Adams, M ;
Vegh, P ;
Andrew, M .
PEDIATRIC RESEARCH, 1998, 44 (03) :351-356
[9]  
BESBAS N, 1994, EUR J PEDIATR, V153, P891, DOI 10.1007/BF01954739
[10]   Bacterial induction of autoantibodies to β2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome [J].
Blank, M ;
Krause, I ;
Fridkin, M ;
Keller, N ;
Kopolovic, J ;
Goldberg, I ;
Tobar, A ;
Shoenfeld, Y .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (06) :797-804